Insider Selling: Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the transaction, the insider directly owned 50,366 shares of the company’s stock, valued at $1,263,682.94. The trade was a 64.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kinney Horn also recently made the following trade(s):

• On Tuesday, July 7th, Kinney Horn sold 1,092 shares of Immunome stock. The stock was sold at an average price of $25.00, for a total value of $27,300.00.

Immunome Stock Up 1.2%

Shares of NASDAQ IMNM traded up $0.30 during midday trading on Thursday, reaching $25.82. 832,002 shares of the stock were exchanged, compared to its average volume of 1,389,713. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -10.85 and a beta of 2.08. The firm has a 50-day simple moving average of $21.36 and a two-hundred day simple moving average of $22.12. Immunome, Inc. has a twelve month low of $8.66 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. Research analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunome

Several large investors have recently bought and sold shares of IMNM. KBC Group NV acquired a new position in shares of Immunome during the first quarter valued at approximately $60,000. Strs Ohio acquired a new stake in shares of Immunome in the fourth quarter worth approximately $64,000. Assetmark Inc. increased its position in shares of Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares in the last quarter. State of Wyoming purchased a new stake in shares of Immunome during the second quarter worth approximately $109,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Immunome in the 4th quarter valued at $121,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IMNM. Barclays assumed coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Truist Financial lifted their price target on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.